title: Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.
authors: E
authors: E
authors: Scherman
authors: S
authors: S
authors: Malak
authors: C
authors: C
authors: Perot
authors: N C
authors: NC
authors: Gorin
authors: M T
authors: MT
authors: Rubio
authors: F
authors: F
authors: Isnard
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007621:Karyotyping; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics; D012306:Risk; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide; D001374:Azacitidine